论文部分内容阅读
细胞源性异种移植(cell line-derived xenografts,CDX)与原发肿瘤相比失去了肿瘤的异质性和基因的多样性,在临床前的实验中不能有效评估肿瘤药物的疗效和安全性,致使临床药物高消耗而没有达到治疗疾病的目的,严重阻碍了临床药物的发展;人源性肿瘤组织异种移植(patient-derived tumor xenografts,PDTX)保持了原发肿瘤的分子学、基因学和病理学特征,而且经过在小鼠体内传代它仍保持了原发肿瘤的这些特性,为肿瘤的个体化治疗提供了更好的模型。PDTX模型的这些特性与CDX模型相比在肿瘤的个体化治疗方面更具有指导意义。本文将就PDTX模型的特征及其在肿瘤研究领域中的应用作系统阐述。
Cell line-derived xenografts (CDX) lose tumor heterogeneity and gene diversity compared with primary tumors, and can not effectively assess the efficacy and safety of oncology drugs in preclinical experiments. Leading to high consumption of clinical drugs without the purpose of treatment of diseases, seriously hindered the development of clinical drugs; human-derived tumor xenografts (patient-derived tumor xenografts, PDTX) to maintain the primary tumor molecular biology and genetics Neo-confucianism, and these characteristics of primary tumors after being passaged in mice provide a better model for the individualized treatment of tumors. These features of the PDTX model are more instructive in the individualized treatment of tumors than the CDX model. This article will describe the characteristics of the PDTX model and its application in the field of cancer research.